1. Introduction {#sec1}
===============

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among females of reproductive age, with a worldwide prevalence of 5--20% depending on the criteria used \[[@B1], [@B2]\]. The main manifestations of this syndrome are ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology \[[@B2]\]. Noticeably, PCOS is associated with several metabolic disturbances such as insulin resistance, compensatory hyperinsulinemia, dyslipidemia, and central obesity, which increases the risk for long-term complications such as type 2 diabetes mellitus, metabolic syndrome, and cardiovascular diseases \[[@B3]\]. Moreover, previous data demonstrated that, compared to normo-ovulatory women, PCOS patients might exhibit a dysregulation in the IGF system represented as an elevation in the serum levels of free insulin-like growth factor-1 (IGF-1) and a reduction in the serum levels of insulin-like growth factor binding protein-1 (IGFBP-1) \[[@B4]\]. The IGF system plays an important role in the regulation of oocyte maturation, folliculogenesis, ovarian steroidogenesis, and metabolism \[[@B5], [@B6]\]. Thus, abnormality in the IGF system may play a role in the pathogenesis of PCOS. IGF-1 is a growth factor with an endocrine action. It is mostly synthesized by the liver but it is also produced by other tissues, including the ovaries, where it has autocrine/paracrine functions \[[@B5]\]. The function and bioavailability of IGF-I are modulated by six binding proteins (IGFBP 1--6) and their proteases \[[@B6]\]. Among the six IGFBPs, IGFBP-1 is the most important binding protein with regard to insulin and glucose metabolism \[[@B7]\]. The IGFBP-1 gene contains an insulin-sensitive response element that directly suppresses its transcription in response to increased hepatic insulin exposure \[[@B6]\]. However, the exact aetiology of PCOS remains unclear and current treatments are only moderately effective at controlling PCOS symptoms and preventing its complications \[[@B8]\]. Thus, seeking for alternative or adjuvant therapies, numerous studies investigated the impact of dietary supplements such as zinc \[[@B9]\], inositol \[[@B10]\], omega-3 fatty acids \[[@B11]\], and vitamins \[[@B12]\] in management of this syndrome. Some of those studies focused on vitamin D. Vitamin D is no longer considered a vitamin solely responsible for regulating bone metabolism and maintaining calcium homeostasis as several studies demonstrated its influence on cell proliferation, differentiation, apoptosis, immune regulation, genome stability, and neurogenesis \[[@B13]\]. Growing evidence suggests a role of vitamin D in female reproductive diseases, as the expression of vitamin D receptors (VDRs) was identified in many organs throughout the female reproductive tract, such as ovary (particularly, granulosa cells), uterus, and placenta \[[@B14]\]. Animal studies revealed that VDR null female mice were infertile and they exhibited uterine hypoplasia and impaired folliculogenesis \[[@B15]\]. On the top of that, vitamin D regulates over 300 genes, including genes that are important for glucose and lipid metabolism. Thus, vitamin D deficiency may be the missing link between insulin resistance and PCOS \[[@B3]\]. Moreover, vitamin D deficiency is a common condition among women with PCOS \[[@B16], [@B17]\], and several studies indicated an association between low levels of serum 25-hydroxyvitamin D (25-OH-vitamin D) and manifestations of PCOS including insulin resistance \[[@B16]--[@B20]\], hyperandrogenism \[[@B18]\], and infertility \[[@B21], [@B22]\]. Besides, abnormalities in calcium homeostasis and PTH levels secondary to vitamin D deficiency may be responsible for the arrested follicular development and menstrual dysfunction in women with PCOS \[[@B23]\]. Further, a recent in vitro study \[[@B24]\] showed that vitamin D regulated steroidogenesis and IGFBP-1 production in cultured human ovarian cells, and many reports have suggested an interrelation between IGF-1 and vitamin D \[[@B25]\]. However, supplementation of PCOS patients with calcium and vitamin D, with or without metformin, led to divergent outcomes on follicles maturation and menstrual cycle regulation \[[@B23], [@B26]--[@B28]\], and no previous study investigated the effects of calcium or vitamin D supplements on the IGF-1 system in this population. Considering the aforementioned data, we conducted this placebo-controlled clinical trial to assess the effect of calcium and vitamin D supplements as an adjuvant therapy to metformin on menstrual cycle abnormalities, gonadotropins, and IGF-1 system in vitamin D-deficient/insufficient PCOS women.

2. Materials and Methods {#sec2}
========================

2.1. Study Design {#sec2.1}
-----------------

This randomized, single-blinded, placebo-controlled clinical trial was conducted on women with PCOS who referred to the outpatient clinic at Damascus University of Obstetrics and Gynecology Hospital and Orient Hospital, in Damascus, Syria, from December 2016 to December 2017. The Ethical Committee of Damascus University approved the study protocol, and a written informed consent was obtained from all participants. The clinical trial registration number is [NCT03792984](https://clinicaltrials.gov/ct2/show/NCT03792984).

2.2. Participants {#sec2.2}
-----------------

In this study, we included PCOS women aged 18--30 years. The diagnosis of PCOS was done according to the Rotterdam criteria \[[@B29]\] and the presence of at least two of the following three criteria: (1) oligo or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, (3) polycystic ovarian morphology on ultrasound examination (defined as the presence of 12 or more follicles in each ovary measuring 2--9 mm in diameter and/or an ovarian volume \>10 ml). Patients who were diagnosed with androgen-secreting tumours, Cushing\'s syndrome, congenital adrenal hyperplasia, hyperprolactinemia, hypercalcemia, malabsorption disorders, diabetes mellitus, thyroid disorders, liver disease, renal disease, history of kidney stones, epilepsy, or cardiovascular disease were excluded. Pregnant, postpartum, or breastfeeding women were excluded as well. All women at the baseline were vitamin D-deficient or insufficient according to the Endocrine Society Clinical Practice Guideline \[[@B30]\]. All study participants reported no use of any hormonal therapy, corticosteroids (other than topical corticosteroids forms), insulin sensitizers, hypolipidemic agents, anti-obesity medications, vitamin D or calcium supplements, anti-epileptic drugs, or any other drugs known to affect endocrine parameters, carbohydrate metabolism, or calciotropic hormone concentrations during the last 3 months. Every patient who met the inclusion criteria and approved to participate in this trial had a face-to-face interview at the baseline to answer a comprehensive questionnaire, which embraced; age, family disease history, smoking habits, alcohol drinking habits, sunscreens usage habits, dress code, and the length of outdoor exposure to the sunlight. All women were advised to maintain their usual dietary habits and not to modify other lifestyle factors such as sunlight exposure or physical activity during the study period.

2.3. Intervention, Randomization, and Blindness {#sec2.3}
-----------------------------------------------

Patients were randomly assigned into two study groups when they came back in the early follicular phase (2--5 days of menses) of a spontaneous or induced menstrual cycle. Patients in group A received metformin and placebo; patients in group B received metformin, calcium carbonate, and vitamin D~3~ (cholecalciferol). All treatments were given orally for 8 weeks. The metformin dose was increased stepwise (starting with 500 mg once daily for the 1^st^ week and 500 mg twice daily in the 2^nd^ week, followed by 500 mg 3 times daily from the 3^rd^ week onward). The dose of calcium carbonate (1000 mg/daily) and vitamin D~3~ (6000 IU/daily) remained constant throughout the study period. Simple randomization was done using a randomized table created by computer software (Random Allocation Software Version 1.0.0, Isfahan, Iran). The allocation was not concealed and allocation ratio was 1 : 1. Only the patients were blinded to the identity of the treatment group.

2.4. Clinical Assessment {#sec2.4}
------------------------

Standard anthropometric data were obtained from each subject (height, weight, waist circumference, and hip circumference), in an overnight fasting status without shoes with light clothes, at the baseline and after 8 weeks of intervention. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m^2^). Menstrual regularity was assessed as the presence of a menstrual cycle with 21--35 days. Hirsutism was evaluated using the modified Ferriman--Gallwey score (m-FGS) \[[@B31]\], with a threshold (m-FGS) ≥6.

2.5. Assessment of Biochemical Variables {#sec2.5}
----------------------------------------

All assays were conducted at the laboratories of Damascus University of Obstetrics and Gynecology Hospital. All blood samples were taken after an overnight fast (≈10 hours of fasting). We took 10 millilitres of venous blood from each participant at the baseline during the early follicular phase (2--5 days of menses) of a spontaneous or induced menstrual cycle. After 8 weeks of intervention, other samples were taken to assess the final levels of all biological parameters except for LH and FSH, which were assayed from samples obtained during the early follicular phase of a spontaneous menstrual cycle. Samples were centrifuged at 4000 rpm for 10 min to separate serum. Then, the serum was stored at −60°C until assayed. Serum concentrations of IGF-1 were assayed using an ELISA kit from DIAsource ImmunoAssays S.A. (Belgium) after acid-ethanol extraction. Serum concentrations of IGFBP-1 were assayed using an ELISA kit from DIAsource ImmunoAssays S.A. (Belgium). Serum concentrations of LH, FSH, and 25-OH-vitamin D were assayed using immunofluorescence kits from I-CHROMA (Boditech Med Inc., Korea). Calcium and phosphorus were assayed by the colorimetric method using kits from AMS S.p.A. (Italy). The intra-assay coefficients of variation for all assays were less than 10%. The interassay coefficients of variation for all assays were less than 10% except for IGFBP-1 assay, which was less than 15%.

2.6. Statistical Analysis {#sec2.6}
-------------------------

All statistical analyses were performed using a Statistical Package for the Social Sciences (SPSS) software version 24.0 (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean ± standard deviation and categorical variables as counts with percentages. The Kolmogorov--Smirnov test was used to evaluate the normality of data distribution. Between-group comparisons were performed using the independent *t*-test for normally distributed variables, the Mann--Whitney *U* test for nonnormally distributed variables, and chi-square or Fisher\'s exact test as appropriate for categorical variables. Within-group comparisons were performed using the paired *t*-test for normally distributed variables, the Wilcoxon paired rank test for nonnormally distributed variables, and the McNemar\'s test for categorical variables. For testing all hypotheses, tests were two-tailed, and *p* values less than 0.05 were considered statistically significant.

3. Results {#sec3}
==========

Of 82 patients with PCOS, 45 women met the inclusion criteria and participated in the study, of which 5 patients were lost before randomization while waiting for their menses. Forty patients were randomly assigned into two groups, with 20 patients in each group. However, only 34 patients (85%) completed the study (group A: metformin-placebo, *n*=16; group B: metformin-calcium-vitamin D~3~, *n*=18). The details about the study design and subjects lost to follow-up are illustrated in [Figure 1](#fig1){ref-type="fig"}. At the baseline, the two groups did not differ significantly in age, BMI, or other baseline characteristics, as shown in [Table 1](#tab1){ref-type="table"}. After 8 weeks of intervention, calcium and vitamin D co-supplementation led to a significant increase in 25-OH-vitamin D levels and calcium levels in the supplementation group compared to the other group (change in 25-OH-vitamin D levels: +19.38 ± 7.78 vs +0.11 ± 4.79 ng/ml, respectively; *p* value=0.0001) (change in calcium levels: +0.83 ± 0.82 vs +0.01 ± 0.86 mg/dl, respectively; *p* value=0.014), but no significant change was detected in phosphorus levels (change in phosphorus levels: +0.38 ± 0.85 vs +0.26 ± 1.78 mg/dl, respectively; *p* value=0.281) ([Table 2](#tab2){ref-type="table"}). Weight, BMI, waist circumference, hip circumference, and waist-to-hip ratio decreased significantly in both groups, but the means of changes from baseline did not differ significantly between them. Compared to baseline, a significant decrease in LH was observed in group A (*p* value=0.028), a significant increase in FSH was observed in group B (*p* value=0.037), and a significant decrease in LH to FSH ratio was observed in both groups (*p* values=0.027 and 0.003 in groups A and B, respectively). Nevertheless, the means of changes from baseline did not differ significantly between the two groups. As shown in [Table 3](#tab3){ref-type="table"}, an improvement in menstrual cycle irregularity was detected in 38.5% and 58.8% of patients in groups A and B, respectively; but the change was statistically significant only in the supplementation group (*p* value=0.002). No significant changes were noticed in IGFBP-1 levels or IGF-1 to IGFBP-1 ratio in both groups. Furthermore, although a significant decrease in IGF-1 levels was detected in the supplementation group, the means of changes from baseline did not differ significantly between the two groups. Notably, the serum levels of 25-OH-vitamin D levels were normalized in all patients of group B after supplementation without reaching the toxic level (100 ng/ml). No serious adverse effects were observed in any participant in both groups. Two patients in the metformin-placebo group (12.50%) had headache compared to 5 patients in the metformin-calcium-vitamin D group (27.78%), and the differences between the two groups were insignificant (*p* value=0.405). Five patients in the metformin-placebo group (31.25%) had gastrointestinal side effects compared to 3 patients in the metformin-calcium-vitamin D group (16.67%), and the differences between the two groups were insignificant (*p* value=0.429). All side effects were tolerable.

4. Discussion {#sec4}
=============

The results of our study indicated that adding calcium and vitamin D supplements to metformin led to a superior effect on regulation of menstrual cycles in vitamin D-deficient/insufficient subjects with PCOS with no significant effects on serum levels of LH, FSH, LH to FSH ratio, IGF-1, IGFBP-1, or IGF-1 to IGFBP-1 ratio. Recent data revealed that losing weight might improve menstrual irregularity in PCOS patients \[[@B32]\]. However, it is unlikely that the improvement in anthropometric parameters was the main cause of our results, as the means of changes from baseline did not differ significantly between the two groups, and menstrual cycle irregularity improved significantly only in the supplementation group. In agreement with our findings, the single-arm study of Thys-Jacobs et al. \[[@B23]\] showed that treatment of 13 vitamin D-deficient/insufficient PCOS women with calcium (1500 mg/daily) and vitamin D (ergocalciferol (D~2~) 50,000°IU/weekly or biweekly to attain a targeted serum 25-OH-vitamin D concentration of 30--40 ng/ml) for 2 months normalized menstrual cycle irregularity in 7 patients, led to pregnancy in 2 patients, and maintained the menstrual cycle regularity in the other 4 patients who already had normal menstrual cycles before treatment. Moreover, Tehrani et al.\'s study \[[@B26]\] demonstrated that the frequency of regular menstrual cycles and dominant follicles (detected using transabdominal sonography) in vitamin D-deficient PCOS women were higher after treatment with calcium (1000 mg/daily) and vitamin D (50,000 IU/every 2 weeks) supplements in addition to metformin (1500 mg/daily) for 4 months compared to metformin alone, calcium-vitamin D alone, or placebo. However, in this study, both metformin and metformin plus calcium-vitamin D therapies significantly improved menstrual irregularity and follicular maturation with better results in the metformin plus calcium-vitamin D group (45% vs 65% for menstrual irregularity and 50% vs 60% for follicular maturation). On the other hand, Rashidi et al.\'s study \[[@B27]\] showed that treating PCOS subjects with metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D (400 IU/daily) for 3 months led to a significantly higher number of dominant follicles (≥14 mm) during the further 2--3 months of follow-up compared to treatment with metformin alone or calcium-vitamin D alone using transvaginal sonography. Besides, the follicular response was relatively higher in the calcium-vitamin D group compared to the metformin group, but the differences between the groups were statistically insignificant. In addition, the improvement in menstrual irregularity after 3 months of intervention was more noticeable in the metformin plus calcium and vitamin D group, though the differences between the groups were also statistically insignificant. Differently, Firouzabadi et al.\'s study \[[@B28]\] showed a better improvement in menstrual irregularity, follicle maturation (detected using transvaginal sonography), and infertility after treating PCOS patients with metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D (100,000 IU/monthly) for 6 months compared to metformin alone, but these results were statistically insignificant. It is worth mentioning that except for Tehrani et al.\'s study, previous studies were lack of blindness or placebo controlling. Considering that the differences between the results could be stemmed from the differences in the study designs, the methods were used to detect follicular maturation, baseline vitamin D status, treatment strategies (dose and duration of vitamin D supplementation), and levels of vitamin D after treatment. In our trial, all participants were vitamin D-deficient or insufficient at the baseline (had baseline 25-OH-vitamin D less than 30 ng/ml), and treatment with vitamin D supplements normalized 25-OH-vitamin D levels in all subjects in the supplementation group. So far, the potential mechanism by which vitamin D influences folliculogenesis is still unclear. In the present study, we could not detect any superior effects on improving serum levels of LH, FSH, or LH to FSH ratio in the supplementation group compared to the other group. This is consistent with the results reported by Selimoglu et al.\'s \[[@B33]\] and Irani et al.\'s \[[@B34]\] studies. However, some reports have suggested that vitamin D effects on folliculogenesis may be mediated by its impact on anti-Mullerian hormone (AMH), in addition to its effect on regulation of calcium homeostasis as the latter plays an important role in oocyte activation and maturation resulting in the resumption and progression of follicular development \[[@B14], [@B23]\]. AMH is a glycoprotein produced by granulosa cells of primary, preantral, and small antral follicles \[[@B14]\]. AMH levels rise in women with PCOS and may play a role in the pathophysiology of this syndrome \[[@B35]\], as AMH inhibits the recruitment of primordial follicles, decreases the follicular sensitivity to FSH, and inhibits granulosa cell aromatase, leading to an increase in intrafollicular androgen levels \[[@B14], [@B36]\]. In vitro studies showed that the human AMH gene promoter contains a functional vitamin D responsive element (VDRE) \[[@B37]\], and treating human cumulus granulosa cells with vitamin D led to a downregulation in AMH receptor-II (AMHR-II) \[[@B38]\]. Furthermore, a recent interventional study revealed that treating PCOS women with vitamin D supplements normalized their serum AMH levels. However, this effect was not observed in the control subjects \[[@B36]\]. On the other hand, Asemi et al.\'s study \[[@B39]\] showed an improvement in insulin sensitivity after supplementation of PCOS subjects with calcium and vitamin D supplements. Several published reports confirmed the expression of VDR and 25-hydroxy-vitamin D3-1*α*-hydroxylase in pancreatic islets \[[@B40], [@B41]\]. Furthermore, vitamin D may activate the transcription of human insulin receptor gene as the promoter of this gene has a vitamin D responsive element (VDRE) \[[@B42]\], besides its effects on regulation of extracellular and intracellular calcium as insulin secretion from *β* cells is a calcium-dependent process \[[@B43]\]. Thus, the beneficial effects of calcium and vitamin D in management of PCOS subjects may be a result of maintaining calcium homeostasis, improving insulin sensitivity, and reducing AMH level. However, further studies are needed to confirm that.

Concerning IGF-1 system, several studies have suggested a bidirectional link between IGF-1 and vitamin D. However, both vitamin D and IGF-I are largely expressed throughout the body and have a broad spectrum of effects so their interrelations are extremely complex \[[@B25]\]. Data from previous in vitro and animal studies demonstrated that IGF-1 could be a regulator of renal 25-OH-vitamin D-1*α*-hydroxylase \[[@B44], [@B45]\]. On the other hand, VDR knockout mice exhibited reduced levels of plasma IGF-I compared to the wild-type mice \[[@B46]\]. An in vitro study on cultured human fetal epiphyseal chondrocytes disclosed that vitamin D stimulated the expression of IGF-1, IGFBP-3, and growth hormone receptor (GHR) \[[@B47]\]. Some reports hypothesized that vitamin D may influence circulating IGF-1 by targeting the liver, as this organ accounts for most IGF-I in the bloodstream and nonparenchymal hepatic cells (stellate, Kupffer, and sinusoidal endothelial) strongly express the VDR and contribute to the pool of liver-derived circulating IGF-I \[[@B25]\]. However, studies on human subjects ended up with inconsistent outcomes. The study of Hyppönen et al. \[[@B48]\] showed a positive correlation between 25-OH-vitamin D and IGF-I, with a linear increase in IGF-1 until 25-OH-vitamin D concentrations reached 30--34 ng/ml, after which this effect reached a plateau. On the other hand, Bogazzi et al.\'s study \[[@B49]\] on healthy subjects demonstrated a positive correlation between 25-OH-vitamin D and IGF-I through all values of vitamin D with serum IGF-I concentrations significantly lower in individuals with severe vitamin D deficiency than those with mild-to-absent deficit. Differently, Lumachi et al. \[[@B50]\] did not notice any correlation between 25-OH-vitamin D and IGF-1 in elderly women, while Trummer et al. \[[@B51]\] showed that, in subjects with arterial hypertension, IGF-1 significantly correlated with 1,25-(OH)~2~-vitamin D but not with 25-OH-vitamin D. On the contrary, Zofková et al. \[[@B52]\], in their study about age-associated bone loss in women, did not notice any associations between IGF-I levels and serum 25-OH-vitamin D or 1,25-(OH)~2~-vitamin D. We have to keep in mind that different commercial IGF-I assay kits can give very different results for the same sample, with up to a 2.5-fold difference between the lowest and highest values. This intermethod variability is generally explained by calibration against different IGF-I reference preparations and differences in the efficiency of methods used to remove IGFBPs \[[@B53]\]. However, since association does not mean causation, intervention studies are necessary to prove the latter. Recently, Al-Daghri et al. \[[@B54]\] showed that treating vitamin D-deficient subjects with vitamin D supplements for 6 months (50,000 IU/weekly for the first 2 months, then twice a month for 2 months, followed by 1000 IU/daily in the last 2 months) led to a significant increase in IGF-1 and IGF-1 to IGFBP-3 ratio. Moreover, Ameri et al. \[[@B55]\] noticed an increase in IGF-1 after treatment with vitamin D supplements with a dose 7000 IU/weekly for 12 weeks compared to a dose 5000 IU/weekly or controls (controls received no intervention), so they suggested that the effect was dose dependent. However, both studies were not blinded or placebo-controlled. Actually, the result of our study was in line with previous randomized placebo-controlled trials. A study on Latino and African American vitamin D-deficient/insufficient prediabetes subjects \[[@B56]\] could not detect any significant effects on serum IGF-1 after treatment with a high dose of vitamin D supplements (85,300 IU ± 16,000) for one year. Neither could Trummer et al. \[[@B51]\] in their short-term (8 weeks) study on vitamin D-deficient/insufficient hypertension patients using 2800 IU/daily of vitamin D. Thus, despite using a higher dose than was used in Ameri et al.\'s study, those studies failed to detect any significant effect on IGF-1 in short-term or long-term period in vitamin D-deficient/insufficient subjects. Nevertheless, we have to keep in mind that these results were obtained from subjects who belonged to different study populations with different patient\'s medical records. Recent data showed that many drugs may affect the IGF system like ACE inhibitors (drugs are used for management hypertension) \[[@B57]\] and statins \[[@B58], [@B59]\] (drugs are used for management dyslipidemia). Thus, concurrent drug usage may be a confounder affecting the outcomes. However, our subjects were not taken any drugs might affect the IGF-1 system or other hormonal or metabolic parameters except for the studied treatments.

To our best knowledge, this is the first randomized, single-blind, placebo-controlled interventional study that investigates the effect of calcium and vitamin D supplements as an adjuvant therapy to metformin on menstrual cycle abnormalities, gonadotropins, and IGF-1 system in vitamin D-deficient/insufficient PCOS women as the latter issue has never been addressed before. On the other hand, some limitations must be considered in the interpretation of our findings. The main limitations of the present study are the small sample size and the absence of follicular growth evaluation on ultrasound examination at the end of the study. Besides, due to lack of budget, we did not assess the effect of studied treatments on other IGFBPs.

5. Conclusions {#sec5}
==============

Calcium and vitamin D can support metformin effect on regulation of menstrual cycle irregularity in vitamin D-deficient/insufficient PCOS patients, but this effect is not associated with any significant changes in gonadotropins or IGF-1 system. These results suggest a possible role of calcium and vitamin D supplements in management of PCOS. However, further studies are needed to identify the underlying mechanisms.
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###### 

Baseline characteristics of study subjects in both groups.

  Variables                                                        Metformin + placebo (*n*=16)   Metformin + calcium + vitamin D~3~ (*n*=18)   *P* value
  ---------------------------------------------------------------- ------------------------------ --------------------------------------------- -----------
  Age (years)                                                      23.38 ± 3.54                   23.06 ± 3.32                                  0.788
  Weight (kg)                                                      71.39 ± 14.79                  64.29 ± 13.02                                 0.147
  Height (cm)                                                      159.29 ± 7.84                  158.86 ± 5.59                                 0.853
  BMI (kg/m^2^)                                                    28.01 ± 4.41                   25.48 ± 4.97                                  0.128
  Family history of DM, % (*n*)                                    50.0 (8)                       27.8 (5)                                      0.291
  Family history of CVD, % (*n*)                                   37.5 (6)                       61.1 (11)                                     0.303
  Family history of thyroid diseases, % (*n*)                      0.0 (0)                        16.7 (3)                                      0.230
  Family history of PCOS, % (*n*)                                  25.0 (4)                       27.8 (5)                                      1.000
  Smoking, % (*n*)                                                 50.0 (8)                       27.8 (5)                                      0.291
  Drinking alcohol, % (*n*)                                        6.3 (1)                        5.6 (1)                                       1.000
  Menstrual irregularity, % (*n*)                                  81.3 (13)                      94.4 (17)                                     0.323
  Hirsutism, % (*n*)                                               75.0 (12)                      77.8 (14)                                     1.000
  Daily outdoors exposure to the sunlight: \>30 minutes, % (*n*)   62.5 (10)                      44.4 (8)                                      0.327
  Sunscreen use, % (*n*)                                           62.5 (10)                      61.1 (11)                                     1.000
  Hijab, % (*n*)                                                   75.0 (12)                      61.1 (11)                                     0.477

BMI: body mass index; DM: diabetes mellitus; CVD: cardiovascular diseases; PCOS: polycystic ovary syndrome.

###### 

Clinical and hormonal parameters of study subjects in both groups before and after 8 weeks of intervention.

                             Metformin + placebo (*n*=16)   *P* value^*∗*^   Metformin + calcium + vitamin D~3~ (*n*=18)   *P* value^*∗*^   *P* value^\#^     *P* value^‡^                                       
  -------------------------- ------------------------------ ---------------- --------------------------------------------- ---------------- ----------------- ---------------- ---------------- -------- ------- --------
  Weight (kg)                71.39 ± 14.79                  70.48 ± 15.19    −0.91 ± 1.67                                  0.047            64.29 ± 13.02     62.54 ± 13.10    −1.76 ± 2.23     0.004    0.147   0.223
  BMI (kg/m^2^)              28.01 ± 4.41                   27.63 ± 4.35     −0.39 ± 0.66                                  0.032            25.48 ± 4.97      24.78 ± 4.99     −0.70 ± 0.90     0.004    0.128   0.255
  Waist circumference (cm)   90.88 ± 12.66                  88.75 ± 13.53    −2.13 ± 2.09                                  0.007            84.61 ± 10.43     81.58 ± 10.31    −3.03 ± 3.12     0.003    0.124   0.135
  Hip circumference (cm)     106.25 ± 9.12                  104.94 ± 9.28    −1.31 ± 1.35                                  0.001            103.50 ± 10.46    101.28 ± 10.57   −2.22 ± 2.13     0.0001   0.423   0.153
  Waist/hip                  0.85 ± 0.06                    0.84 ± 0.07      −0.01 ± 0.02                                  0.026            0.82 ± 0.04       0.80 ± 0.04      −0.01 ± 0.03     0.039    0.088   0.825
  LH (mIU/ml)                10.03 ± 5.55                   6.86 ± 3.76      −3.17 ± 5.20                                  0.028            7.73 ± 5.17       6.10 ± 3.23      −1.63 ± 3.04     0.149    0.144   0.403
  FSH (mIU/ml)               6.33 ± 2.10                    6.89 ± 1.91      0.56 ± 1.16                                   0.073            5.45 ± 1.73       6.17 ± 1.67      0.72 ± 1.36      0.037    0.187   0.707
  LH/FSH                     1.77 ± 1.26                    1.02 ± 0.48      −0.74 ± 1.22                                  0.027            1.45 ± 0.94       1.04 ± 0.68      −0.41 ± 0.51     0.003    0.506   0.721
  IGF-1 (ng/ml)              193.61 ± 90.25                 184.33 ± 72.39   −9.28 ± 93.01                                 0.695            208.56 ± 106.52   180.35 ± 86.72   −28.21 ± 46.33   0.019    0.664   0.450
  IGFBP-1 (ng/ml)            5.59 ± 5.47                    4.71 ± 3.30      −0.88 ± 5.48                                  0.918            7.42 ± 6.14       7.50 ± 8.73      0.08 ± 6.32      0.879    0.368   0.959
  IGF-1/IGFBP-1              89.69 ± 123.30                 91.02 ± 126.77   1.33 ± 84.84                                  0.951            76.01 ± 104.57    43.61 ± 37.54    −32.40 ± 74.49   0.231    0.463   0.670
  Vitamin D (ng/ml)          19.88 ± 3.92                   19.99 ± 5.78     0.11 ± 4.79                                   0.928            20.42 ± 6.10      39.80 ± 5.55     19.38 ± 7.78     0.0001   0.764   0.0001
  Calcium (mg/dl)            9.40 ± 0.71                    9.41 ± 0.66      0.01 ± 0.86                                   0.977            9.09 ± 0.43       9.92 ± 0.84      0.83 ± 0.82      0.0001   0.126   0.014
  Phosphorus (mg/dl)         3.82 ± 0.83                    4.08 ± 1.51      0.26 ± 1.78                                   0.875            3.56 ± 0.72       3.94 ± 0.50      0.38 ± 0.85      0.072    0.330   0.281

BMI: body mass index; LH: luteinizing hormone; FSH: follicle-stimulating hormone; IGF-1: insulin-like growth factor-1; IGFBP-1: insulin-like growth factor binding protein-1; ^*∗*^within-group comparison between baseline and 8 weeks of intervention (pretest vs posttest); ^\#^between-group comparison at baseline (pretest metformin-placebo group vs pretest metformin-calcium-vitamin D~3~ group); ^‡^: between-group comparison in means of changes from baseline (posttest minus pretest) (means of changes in metformin-placebo group vs means of changes in metformin-calcium-vitamin D~3~ group).

###### 

Improvement in menstrual irregularity in both groups after intervention.

                                                   Metformin + placebo (*n*=16)   *P* value   Metformin + calcium + vitamin D~3~ (*n*=18)   *P* value
  ------------------------------------------------ ------------------------------ ----------- --------------------------------------------- -----------
  Improvement in menstrual irregularity, % (*n*)   38.5% (5/13)                   0.062       58.8% (10/17)                                 0.002

[^1]: Academic Editor: Masahiro Oike
